CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 15 enrolled
Drug / intervention
vismodegib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01631331
NCT01631331Early Ph 1Completed
CompareCT.gov

A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCCs)

Stanford University·interventional·Posted Jun 29, 2012·Updated Dec 8, 2017

In Brief

A Early Phase 1 clinical trial evaluating vismodegib and Mohs surgery for Basal Cell Carcinoma of the Skin and Recurrent Skin Cancer. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBasal Cell Carcinoma of the Skin, Recurrent Skin Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), University Hospitals Cleveland Medical Center

Timeline

Early Ph 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 29, 2012
Enrollment StartJun 1, 2012
Primary CompletionSep 17, 2015
Study CompletionMay 31, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.0 years ago

Interventions

vismodegibdrug

Given PO

Mohs surgeryprocedure

Undergo Mohs surgery